By Liz BrodyPublished for Oprah daily on Jan 28, 2025
(…)
Of course, that’s still out of reach for many people. Qato’s research in JAMA Health Forum hits on the hard truth of the inequity playing out. While obesity disproportionately affects those on Medicare and Medicaid, in 2023, nearly 90 percent of Wegovy prescription fills were for those covered by commercial plans. “You probably see a fourfold greater use among white, higher-income individuals than in lower-income individuals, especially in people of color,” she says, “and that disparity is among the greatest, widest, largest terms of medication use in the adult population we’ve seen, especially for drugs that improve your life expectancy. The people that need this treatment most are not getting it.”
…
Read more here